Antifilaggrin antibodies comprise a heterogeneous population of antibodies directed to citrullinated proteins. Recent studies have shown that their production is highly specific for rheumatoid arthritis (RA) and the initial antigenic trigger for these autoantibodies can be localised to the inflammed synovial tissue. The aim of our study was to compare the reactivity and specificity of antibodies in sera and synovial fluids towards citrullinated epitopes. Peptide sequence corresponding to human profilaggrin (amino acid residues 306-324) and sequences with citrulline substitution at different positions were synthetised by mutipin peptide synthesis on solid supports. Shortened versions of the peptide were also produced by removal of amino acid residues from its N and C terminals. Completely citrullinated variant of the 14-mer peptide was also prepared. Peptide with no citrulline replacement was used as a control antigen. We found significant differences in the sensitivity for RA of 19 individual peptides tested (from 5% to 68%), reflecting previous results that the surrounding amino acids play an important role in creation of an autoantigenic epitope. Further, we tested the reactivities of paired serum and synovial fluids and found very similar peptide recognition patterns in serum and synovial IgG from the same individuals. Studies on larger number of samples are in progress to evaluate the results statistically that may support further evidence of the synovial origin of antifilaggrin autoantibodies. Acknowledgement: This work was supported by the Hungarian grant OTKA T037876.
Analysis of the peptidylarginine deiminase V gene in rheumatoid arthritis
Sjögren's syndrome (SS) is characterized by exocrine gland destruction associated with lymphocytic infiltrations and chronic autoimmune antigen-driven responses against the intracellular Ro/SSA and La/SSB ribonucleoproteins. Epithelial cells, which are the main targets of autoimmune responses, appear to have a central role in the pathogenesis of SS. In recent years we have presented evidence indicating that salivary gland epithelial cells (SGECs) of SS patients are inherently capable of functioning as antigen-presenting cells. Recently, a novel, cell-free mechanism of antigen presentation has been identified. This mechanism involves exosomes, which are small (30-200 nm) membrane vesicles of endosomal origin secreted by a variety of cell types, such as reticulocytes, B lymphocytes and dendritic cells. In the present study we investigated the capacity of cultured SGEC lines established from SS patients and disease controls to release exosomal vesicles that contain intracellular ribonucleoproteins. Membrane vesicles were isolated by differential centrifugation from SGEC culture supernatants and their nature was confirmed by electron microscopy. Cultured SGECs from patients and controls secreted significant amounts of exosomal vesicles, in a manner largely indistinguishable from other exosomesecreting cells. Exosome release was not associated with apoptosis or other cellular destruction processes. SGEC-derived exosomes were found by Western blot analysis to contain Ro/SSA, La/SSB, and Sm ribonucleoproteins. Our results indicate that SGECs are capable of secreting exosomes. This mechanism may represent a pathway through which intracellular epithelial antigens are exported and subsequently presented to the immune system. In this context, exosomes produced by epithelial cells may have a role in the pathogenesis of SS.
S5 not (Fig. 1) . Furthermore, about 50% of the OA sera and none of the control or RA sera reacted very strongly against lysate components of the different cell lines tested. The corresponding synovial fluids reacted against the same lysate components, but the signals obtained were of reduced intensity.
Conclusion:
Our results demonstrate the presence of autoantibodies in sera and synovial fluid in about half the OA patients. The specificities of these autoantibodies are not restricted to the joints, as reactivity was detected towards any cell line tested. Hoping to design new diagnostic tools and to shed light on the role of autoantibodies in the development and progression of OA, we are in the process of identifying the corresponding autoantigens.
The antiphospholipid syndrome (APS) is characterized by the presence of pathogenic autoantibodies against β 2 -glycoprotein I (β2GPI). The factors causing production of anti-β2GPI remain unidentified, but an association with infectious agents has been reported. We recently identified a hexapeptide (TLRVYK) that is recognized specifically by a pathogenic anti-β 2 GPI monoclonal antibody. In the present study we evaluated the APS-related pathogenic potential of microbial pathogens, which share structural homology with the this hexapeptide. Mice were immunized with a panel of TLRVYK-related microbial particles and were studied for the development of mouse anti-β2GPI autoantibodies. Mouse IgG specific to the TLRVYK peptide were affinity purified from the immunized mice and passively infused i.v. into naive mice at day 0 of pregnancy. APS parameters were evaluated in the infused mice on day 15 of pregnancy. Following immunization, high titers of anti-peptide, anti-β 2 GPI antibodies were observed in mice immunized with Haemophilus influenzae, Neisseria gonorrhoeae or tetanus toxoid. Naive mice infused with the affinity-purified anti-peptide antibodies had a significant thrombocytopenia, prolonged aPTT and elevated percentage of fetal loss, similar to the findings in a control group of mice immunized with a pathogenic anti-β2GPI monoclonal antibody. Our study establishes a mechanism of molecular mimicry in experimental APS, demonstrating that bacteria homologous with β2GPI structure are able to induce the generation of pathogenic anti-β2GPI antibodies along with APS manifestations.
Using various FcγR-deficient mice, we have obtained suggestive evidence that FcγRI on macrophages is responsible for severe cartilage destruction during arthritis mediated by immune complexes (ICs) and Th1 cells. In contrast, in arthritis mediated solely by ICs, FcγRIII seems more important. This suggests that T-cell-mediated FcγRI up-regulation promotes pronounced cartilage destruction. A likely Th1-cell-derived cytokine mediating FcγRI expression is interferon-γ (IFN-γ). In the present study we investigated whether IFN-γ is able to up-regulate cartilage destruction during experimental immune complex-mediated arthritis (ICA) and, if so, whether this mechanism is indeed regulated by FcγRI. IFN-γ was locally overexpressed in the murine knee joint prior to ICA induction by the use of adenoviral vectors. This had no significant effect on joint inflammation as studied by histology. However, irreversible cartilage destruction as studied by the degree of chondrocyte death was markedly enhanced. IFN-γ overexpression resulted in a fivefold increase in chondrocyte death, in comparison with the control group, which had received a control adenoviral vector expressing GFP (AdGFP). To study whether this effect of IFN-γ was related to the presence of ICs, IFN-γ was also overexpressed in a naive joint and during zymosaninduced arthritis, which is an IC-independent arthritis model. No severe cartilage destruction was found, implying a crucial role for ICs and their receptors (FcγRs) in the IFN-γ effect. When IFN-γ was overexpressed in murine knee joints, FcγRI mRNA expression was up-regulated in synovial cells. To prove that the aggravation of chondrocyte death by IFN-γ is indeed FcγRI-mediated, ICA was raised in FcγRI -/-. IFN-γ overexpression did not result in significant elevation of joint inflammation either in FcγRI -/-or their wild-type controls. Interestingly, although IFN-γ was overexpressed, chondrocyte death remained absent in FcγRI -/-, whereas in wild-type controls chondrocyte death was highly increased after IFN-γ overexpression. These results indicate that IFN-γ can aggravate cartilage destruction in an IC-dependent fashion, mediated by FcγRI.
Background and objectives:
Autoantibodies to deiminated proteins are known to be the most specific serological marker for the diagnosis of rheumatoid arthritis (RA). We recently showed that deiminated fibrin is the major target of this family of autoantibodies in rheumatoid synovial tissue. We subsequently developed, and validated on a large series of patients with established rheumatic diseases, an ELISA for the detection of circulating autoantibodies to deiminated human fibrinogen (AhFibA). The test was shown to be the most efficient (specific and sensitive) serological criterion for the diagnosis of RA. Methods: We collected 352 sera from patients with arthritides of recent onset (disease duration <1 year). The diagnosis was established after at least 2 years' follow-up. The patients were then classified into two groups, 175 with RA and 177 with non-RA inflammatory rheumatic diseases. The previously developed ELISA, using in vitro deiminated human fibrinogen as immunosorbent, was used for detection and titration of AhFibA. Antibodies to cyclic citrullinated peptide (CCP) were sought in accordance with the manufacturer's procedure (Immunoscan RA, Euro-diagnostica). Rheumatoid factor (RF) was titrated by nephelometry (RF-reagent for Image, Beckman Coulter). Results: The diagnostic sensitivity of AhFibA was found to be significantly higher than those of CCP (P < 0.05) and RF (P < 0.001) ( Table 1 ). The positive predictive values (PPV) of the three tests were all found to be very high and were not significantly different. The negative predictive values (NPV) were too low to be diagnostically useful. Among the AhFibA-positive RA sera 83% were RF-positive, while among the AhFibA-negative, only 13% were RF-positive. Conclusion: Unlike the case with RF, autoantibodies to deiminated proteins are confirmed to be of diagnostic value in early arthritides. The detection of these autoantibodies by ELISA using their synovial target (deiminated fibrin) appears the most efficient method for the diagnosis of early RA.
Objective: Antibodies against both type II collagen and citrulline residue containing peptides can be found in rheumatoid arthritis (RA) patients. We have noted that serum levels of both anticollagen and anticitrulline antibodies show significant decline after inclusion in an early arthritis clinic (EAC) cohort, and wanted to compare their kinetic patterns of disappearance. Methods: Two hundred and fifty-five EAC patients and 80 RA patients were followed for 1 and 5 years, respectively, from the time of initial referral. Anticollagen and anticitrulline antibodies were determined with ELISA at inclusion and after 3 months and 1, 2, 3 and 5 years. Results: At the patients' inclusion, anticollagen and anticitrulline antibodies were found in 6.3% and 48.2%, respectively, of EAC patients and in 11.5% and 61.0% of the patients with definite RA. Serum levels of antibodies against type II collagen declined continously for the entire study period in both groups, being significant already at 3 months after inclusion. Serum levels of anticitrulline antibodies, on the other hand, showed a biphasic pattern. A significant decline from inclusion (for EAC patients at 1 year, and for RA patients at 3 months and at 1 and 2 years) was followed by increased serum levels (significant for RA patients between 2 and 5 years). No correlation was found between changes in serum levels of anticollagen and anticitrulline antibodies at any time. Conclusion: These findings suggest that different immunological events predispose to immunity against collagen type II and against citrulline-containing peptides in RA. The Ro60kD polypeptide is associated with both RNA and the Ro52kD protein.
The specific protein-RNA and protein-protein interactions are thought to occur through the RNP and zinc-finger secondary structure elements located on the 92-161 and 301-327 regions of Ro60kD protein, respectively. The zinc finger domain of Ro60kD is a good candidate to hold a conformational epitope, because both the binding of zinc and the redox conditions can induce specific conformational changes. In this study, we investigated the presence of antibodies against synthetic peptides corresponding to the zinc finger domain of Ro60kD protein (Zif-1b), to a truncated form possessing zinc-binding regions but lacking the intermediate loop and to the intermediate loop (310-319) of the zinc finger domain (Zif-3b). We found that the peptide Zif-1b, corresponding to the native sequence (301-327 aa) of Ro60kD, is recognized by antibodies from the majority (83%) of anti-Ro/La-positive patients with primary Sjögren's syndrome (pSS), in the absence of zinc ions. The same sera failed to react with Zif-1b in the presence of Zn 2+ (2.5%). Its truncated form (Zif-2b) did not react against the same sera, while the peptide corresponding to loop 310-319 (Zif-3b) exhibited high reactivity (85% ) carried out on sera taken at the patients' first visit in discriminating between patients who did (98/270; 36%) and did not have RA at the last visit was evaluated using receiving-operator characteristic curves. To evaluate the combination of anti-CCP with other laboratory tests in discriminating between patients with and without RA, a multiple logistic regression with backward selection using the likelihood ratio test was applied. Results: 1) Anti-CCP, APF and IgG AKA were not perfectly correlated with each other. For anti-CCP EFG (cutoff 53 UI), ESG (cutoff 0.120 OD), and AS (cutoff 0.320 OD), sensitivity and specificity were 47%-93%, 57%-94% and 58%-94%, respectively. 2) By the use of a multiple logistic regression, second generation anti-CCP, IgG-AKA, the latex test and IgM-RF ELISA were selected. Conclusion: ESG and AS are the best tests for predicting RA. Combining one of these tests with IgG-AKA, IgM-RF, and the latex test slightly increases the diagnostic value.
The autoantigen hnRNP-A2 (RA33) is targeted by autoantibodies (autoAbs) of patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD).
To define the humoral autoimmune response in more detail, a series of overlapping peptides covering the N-terminal part hnRNP-A2 known to harbour the major epitopes was studied by ELISA in sera from patients with SLE (n = 40), RA (n = 50), MCTD (n = 11) and other rheumatic diseases (n = 86) and from healthy subjects (n = 29). Antipeptide reactivities were detected in 25% of SLE sera but only rarely in patients with RA or MCTD. Since most of the SLE patients investigated had inactive disease, we next studied sequential sera of 15 individual patients. Of those, only three patients were completely negative for hnRNP-A2 antibodies, while all the other patients showed at least one positive reaction during the observation period. These were directed to the full-length protein and/or to 4 of the 13 peptides used: p35-55, p50-70, p90-116 and p155-175. Interestingly, autoreactivities to the first three peptides were significantly associated with each other but not with reactivity to p155-175 or to the complete protein.
This cluster of reactivity was also not linked to any clinical marker of disease. In contrast, p155-175 was strongly correlated with reactivity to the complete protein (P < 0.001) and both reactivities were associated with autoAb to dsDNA and correlated significantly with clinical disease activity, skin involvement and proteinuria (P < 0.01). Remarkably, immunohistochemical analysis revealed overexpression of hnRNP-A2 in affected skin of SLE patients. These data, together with previously published findings in murine SLE models, are suggestive of an involvement of hnRNP-A2 autoimmunity in the pathogenesis of SLE. (Nat Immunol 2001) . However, this finding remains controversial, since several other groups could not reproduce these results. Given these apparently conflicting findings, we hypothesized that GPI antibodies are present in a specific subset of RA patients and set out to determine at what point autoantibodies to GPI occur in RA. GPI antibodies were detected in only few sera of of uncomplicated RA (2%)and healthy controls (3%). However, in RA patients with disease manifestation outside their joints, GPI antibodies were more common. 18% of RA patients with skin inflammation (rheumatoid nodules) and 45% of RA patients with vascular inflammation had anti-GPI antibodies. Yet, in RA patients with arthritis complicated by decreased numbers of circulating granulocytes (Felty's syndrome) 92% had GPI antibodies. But, since the GPI antigen was not detected on RA granulocytes, we propose that GPI antibodies are not likely to be directly involved in granulocyte destruction. In summary, we conclude that anti-GPI antibodies that cause disease in the KRN mouse model are common in human RA complicated by inflammation outside the joint, demonstrating the relevance of the mouse model to human disease.
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Antibodies directed to citrulline-containing proteins are highly specific for rheumatoid arthritis (RA) and can be detected in up to 80% of RA patients. Citrulline is an unnatural amino acid that can be incorporated into proteins only by post-translational modification of arginine by peptidylarginine deiminase (PAD) enzymes. We investigated the presence of anticitrulline antibodies, PAD enzymes and citrullinated antigens in an acute and a chronic destructive mouse model for arthritis: streptococcal-cell-wall arthritis and collagen-induced arthritis. In both mouse models, PAD2 mRNA is present in the synovium but not translated into PAD2 protein. In contrast, PAD4 mRNA, although absent from healthy synovia, is readily transcribed and translated by polymorphonuclear neutrophils infiltrating the synovial tissue during inflammation. As a consequence, several synovial proteins are subjected to citrullination. One of these proteins was identified as fibrin, which has been reported to S10 be citrullinated also in the synovia of RA patients. Although the generation of citrullinated antigens during synovial inflammation in the mice was eminent, no anticitrullinated protein antibodies could be detected.
In conclusion, the citrullination of synovial antigens is an active process during joint inflammation both in mouse and man, but the induction of autoantibodies directed against these proteins is a more specific phenomenon detectable only in RA patients.
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Fibrinogen-specific T cells in rheumatoid arthritis Rheumatoid arthritis (RA) is characterized by the occurence of autoreactive antibodies and T cells. The family of antibodies directed to citrulline-containing antigens (anti-filaggrin, anti-CCP and anti-Sa) have the highest specificity (>98%) for RA. To investigate the presence of citrulline-specific T cells in RA patients, we analyzed T-cell reactivity to unmodified and citrullinated filaggrin and fibrinogen in modified T-cell proliferation assays. No T-cell responses were observed when either unmodified or citrullinated filaggrin was used as the stimulating antigen in serum-free T-cell proliferation assays. With unmodified fibrinogen, however, T-cell proliferation was observed in 8/15 (53%) of RA patients, while only 1/14 control patients (SLE, SSc, PsoA, Sjö) displayed clearly positive T-cell proliferation. The difference was highly significant (P < 0.0001). These findings were even more pronounced when using citrullinated fibrinogen as stimulating antigen: 10/15 (67%) RA patients were positive for T-cell proliferation and again only 1/14 control patients was clearly positive (P < 0.0001). T-cell reactivity in RA patients was significantly (P < 0.05) higher against citrullinated as compared with unmodified fibrinogen. We conclude that fibrinogen (citrullinated or not) can induce proliferation of RA T cells, thereby further substantiating its pathogenic relevance. Results: In the first two lupus nephritis patients treated with infliximab, proteinuria fell from 1.2 to 0.3 g/24 h and from 5.7 to 1.1 g/24 h, respectively, within 3 months after the start of therapy; the (normal) creatinine serum levels remained stable. Arthritis in a third SLE patient remitted under therapy but relapsed 8 weeks after the last infusion. Anti-dsDNA IgG antibodies increased transiently in all three patients at around week 10 of therapy. An increase in anti-histone antibodies (as well as anti-chromatin antibodies in two of the three patients) predated the increase in anti-dsDNA, which was not associated with increased disease activity. Interestingly, even the increase in anti-histone antibodies was predated by an increase in sTNF (mean ± SD of peak value 168 ± 114 pg/ml), while the percentage of lymphocytes carrying TNF decreased at the same time. Conclusion: Anti-TNF therapy improves SLE glomerulonephritis and arthritis but leads to a transient increase in autoantibodies, which was not associated with flares in our patients. The observation that antidsDNA antibodies are predated by anti-histone antibodies and that this increase follows the changes in TNF suggests that TNF-blocking therapy is directly associated with an increase in anti-histone and a subsequent transient increase in anti-dsDNA antibodies. The -607 C and -137 G alleles were significantly more frequent in the RA population. Highly significant associations (P < 0.001) for RA were found for the homozygous C genotype in positions -607 and -137. Glasgow cohort: The -137 C allele was more frequent in RA patients (P < 0.01), but no effect was seen at position -607. Moreover, the -137CC genotype was more frequent in RA (P < 0.01). However in contrast to the Frankfurt dataset, no effect was seen at the -607 site. Conclusion: SNPs at the -137 position in the IL-18 promoter appear to contribute to the genetic background in RA pathogenesis. Importantly, this has been independently identified in two clinical cohorts, by the use of distinct methodologies, in Germany and the UK. IL-18 is a promising therapeutic target and, as such, defining factors that modulate its regulation in rheumatoid tissues is important. as in rheumatoid arthritis, we investigated the effect of these proinflammatory cytokines on transcription factor activation in osteoblasts. Methods: Osteoblast-like ROS 17/2.8 cells were cultured with IL-1, TNF-α and IL-17 alone and in combination. Effects of each cytokine were explored by RT-PCR and immunocytochemistry. Results: IL-1 and TNF-α induced most of these transcription factors while IL-17 had a weak effect. IL-1 induced egr-1 and all AP-1 member expression, except fosB and junD. TNF-α also induced AP-1 member expression, with a longer expression for fra-1 and fra-2. These two cytokines individually induced nuclear translocation at 30 min, except for JunB. IL-17 enhanced fra-2 and egr-1 mRNA between T30-T120 with a peak at T90, while nuclear localisation was noticed at T30 for Fra-1, JunD and NF-κB. More importantly, when these cytokines were used at low concentrations with no effect when used alone, their combinations showed a synergistic effect on transcription and nuclear translocation of AP-1 members, Egr-1 and NF-κB. Moreover, cytokine combinations allowed an enhanced recruitment of factors not express by cytokines used alone. Conclusion: AP-1, Egr-1 and NF-κB pathways in osteoblast cells are very sensitive to the combined effect of proinflammatory cytokines through additive or synergistic mechanisms. arthritis has yet to be determined. Objective: The objective of this study was to determine the expression of an extensive number of chemokines and their receptors in patients with rheumatoid arthritis (RA) and other forms of arthritis. Methods: Synovial biopsies were obtained with a Parker-Pearson needle from patients with RA (n = 23), osteoarthritis (OA) (n = 16), and reactive arthritis (ReA) (n = 8). ST was studied in patients with both early and late stages of disease. Sections were analyzed by immunohistochemistry using monoclonal antibodies against CD3 (T-cells), CD68 (macrophages), CD13 (aminopeptidase N), CCR1, CCR2b, CCR5, CXCR4, CCL2 (MCP-1), CCL8 (MCP-2), CCL7 (MCP-3), CCL14 (hCC-1), CCL15 (hCC-2), CCL16 (hCC-4), and CCL5 (RANTES). Digital image analysis was used to quantify the staining and for statistical analysis the Kruskal-Wallis H test and the Mann-Whitney U test were used. Results: All chemokines and chemokine receptors were detected in inflamed synovium. There was abundant expression of especially CD13, CCR1, CXCR4, CCR5, CCL7, and CCL8 in all forms of arthritis. The ligands CCL7, CCL8, CCL14, CCL15, and CCL16, which have not previously been described in ST, were all expressed in inflamed ST. The expression of CCL5 (RA, 11182 ± 2239 (mean integrated optical density ± SEM); OA, 8759 ± 2930; ReA, 2081 ± 1181; P = 0.010) and CCL15 (RA, 4993 ± 1601 (mean integrated optical density ± SEM); OA, 1738 ± 573; ReA, 1252 ± 1919; P = 0.043) was significantly higher in rheumatoid ST compared with disease controls.
Expression of chemokines and their receptors in

Conclusion:
These results suggest a potentially important role for a variety of chemokines and their receptors in the migration of inflammatory cells towards the synovial compartment. Disruption of the chemokine network might represent a novel therapeutic approach in RA, but also in other arthritides.
Osteoprotegerin protects from generalized bone loss in TNF-transgenic mice
Background: Chronic inflammatory conditions, such as rheumatoid arthritis, are characterized by generalized loss of bone mass. Proinflammatory cytokines, such as TNF, are believed to play a central role in this process by increasing bone resorption. Objective: We have investigated systemic bone changes in human TNF-transgenic (hTNFtg) mice, which spontaneously develop severe inflammatory arthritis.
Results: Osteodensitometry revealed a significant decrease of trabecular bone mineral density (BMD) (-37%) in hTNFtg mice, and histomorphometry revealed a dramatic loss of bone volume (-85%) in comparison with wild-type controls. Osteoclast-covered bone surface and serum levels of deoxypyridinolin crosslinks were significantly elevated, suggesting increased osteoclast-mediated bone resorption in hTNFtg mice. Osteoprotegerin (OPG) completely blocked TNF-mediated bone loss by increasing BMD (+89%) and bone volume (+647%). Most strikingly, formation of primary spongiosa was dramatically increased (+563%) in hTNFtg mice after OPG treatment. Osteoclastcovered bone surface and serum levels of deoxypyridinolin crosslinks were significantly decreased by OPG, suggesting effective blockade of osteoclast-mediated bone resorption. OPG did not influence levels of hTNF, TNF-receptor-1, IL-1β and IL-6. However, OPG decreased bone formation parameters, which were elevated in hTNFtg mice. In contrast to OPG, bisphosphonates and anti-TNF treatment did not affect generalized bone loss in hTNFtg mice.
Conclusion:
These data indicate that TNF-mediated generalized bone loss is primarily dependent on RANKL/RANK signaling and can be blocked by OPG. Thus, OPG may represent a potent tool to prevent generalized loss of bone mass in chronic inflammatory disorders, especially rheumatoid arthritis. Objectives: For the present study, we investigated the role of endogenous IL-12p40, component of both IL-12 and IL-23, in the pathogenesis of antigen-and chronic relapsing streptococcal-cell-wall-(SCW-) induced arthritis. To this end we used C57Bl6 (wild-type; WT) and IL-12p40-deficient (IL-12 ko) mice. Chronic SCW was induced by intraarticular (i.a.) injection of 25 µg SCW fragments at days 0, 7, 14 and 21. Joint swelling and histology were examined at day 28 after the first injection. Antigen-induced arthritis (AIA) was initiated by i.a. injection of 60 µg mBSA in preimmunized mice. Joint swelling was measured at days 3, 7 and 14, whereas histology was examined at days 7 and 14. Results: At day 28, joint swelling of the mainly macrophage-driven chronic SCW arthritis was significantly reduced in IL-12p40 ko mice in comparison with WT mice (P = 0.0008). Although cell influx was decreased (P = 0.0194), no reduction in cartilage proteoglycan depletion was found. In a predominantly T-cell-mediated process such as AIA, joint swelling was significantly suppressed at days 3 and 7 in IL-12p40 ko mice in comparison with WT (P = 0.0021 and P = 0.0260 respectively). Moreover, histopathology was drastically reduced in IL-12p40 ko mice; the number of inflammatory cells was strongly suppressed in IL-12p40 ko mice in comparison with WT animals (1.6 ± 0.4 vs 0.2 ± 0.2 and P < 0.0001). In line with these findings matrix proteoglycan depletion was completely absent in IL-12p40 ko mice (1.9 ± 0.35 vs 0.05 ± 0.11 and P < 0.0001).
These results indicate that IL-12p40 plays a pivotal role in antigen-induced arthritis and a minor role in chronic relapsing streptococcal-cell-wall-induced arthritis. 
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Conclusion:
Here we showed that IL-18 induces joint inflammation independently of IL-1. In addition, we showed that IL-1 generation, due to IL-18 exposure, was essential for marked cartilage degradation both in vitro and in vivo. These findings imply that IL-18 contributes, through separate pathways, to joint inflammation and cartilage destruction.
Background: T-cell IL-17 is a proinflammatory cytokine present in the synovium of RA patients. IL-17 is an inducer of other cytokines, such as IL-1 and TNF. It can have both additive and synergistic effects on cytokine induction and tissue destruction with these cytokines, but may have direct pathological effects as well.
Objective and methods:
In the present study, we examined the dependency of TNF-α in the IL-17-induced joint inflammation and cartilage damage under naive and arthritis conditions using an adenoviral vector expressing mIL-17 (AdIL-17).
Results: IL-17 overexpression in the knee joint of naive mice resulted in joint inflammation and cartilage proteoglycan depletion, which gradually increased with time. No effects were noted with the same dose of the control vector. IL-17 induced elevated expression of IL-1 mRNA levels in the synovium in comparison with the control group. However, no difference in IL-17-induced joint pathology was noted in IL-1α/β-deficient mice. Of high interest, using TNF-α deficient mice, the IL-17-induced joint inflammation and cartilage damage were almost completely absent. This strongly indicates that under naive conditions in vivo the IL-17-induced joint inflammation and cartilage destruction are mediated by TNF and not necessarily by IL-1.
Since it is known that in streptococcal-cell-wall (SCW) arthritis, TNF and IL-1 induction can be uncoupled, we did similar experiments in this acute SCW arthritis model. Overexpression of T-cell IL-17 in this macrophage-mediated model results in an elevation of joint inflammation and cartilage proteoglycan depletion in comparison with the control vector group. Furthermore, this T-cell cytokine turns this acute model into a more chronic one. Although knocking out TNF-α did have some effect on inflammation and cartilage damage, the dependency of TNF in IL-17 induced pathology was not as strong as under naive conditions. Conclusion: These data show a direct relation of IL-17 and TNF-α induction under naive conditions in vivo. However, the presence of IL-1 during arthritis conditions and the collaboration of IL-17 with IL-1 modulates the TNF-α dependency during arthritis.
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Differential effects of leflunomide and methotrexate on cytokine production in RA Background: T cells are considered to be pivotal cells in the pathogenesis of rheumatoid arthritis (RA) and therefore represent a potential target for treatment. The novel disease-modifying antirheumatic drug (DMARD) leflunomide inhibits pyrimidine biosynthesis. T cells are especially susceptible to inhibition of this enzyme due to increased demand for pyrimidines after activation, together with the absence of a salvage pathway. Objective: We investigated the effects of leflunomide on cytokine profiles in vivo and in vitro to provide more insight into the mechanism of action of leflunomide in RA. Methods: Serum samples from 100 RA patients, treated with either leflunomide (n = 50) or methotrexate (n = 50), were collected at baseline, after 12 weeks and after 1 year of treatment. In these samples, serum levels of interleukin-6 (IL-6) and interferon gamma (IFN-γ) were determined by ELISA. The effects of the active metabolite of leflunomide (A77-1726; 0-200 µM) on IL-6 and IFN-γ production by peripheral blood mononuclear cells (PBMCs) from healthy volunteers (n = 6) and RA patients (n = 3) were studied by ELISA after activation (with phytohemagglutinin, lipopolysaccharide, and αCD3/αCD28) by ELISA. In addition, monocytes and lymphocytes were isolated from two healthy volunteers by density-gradient centrifugation methods, and effects of A77-1726 on IL-6 production after activation (with phytohemagglutinin or lipopolysaccharide) were measured by ELISA and PCR. Effects on cell proliferation ( 3 H-thymidine incorporation), were measured as well.
Results: Serum levels of IFN-γ were significantly reduced after leflunomide treatment (baseline 43 pg/ml ± 10 [mean ± SEM]; 1 year 29 ± 7 [P = 0.015]), whereas we did not observe a change in IL-6 concentrations in serum (baseline 158 ± 41, 4 months 151 ± 48). In contrast, both IFN-γ and IL-6 serum levels were significantly reduced after methotrexate treatment. Consistent with these data, in vitro experiments revealed a dose-dependent inhibition of IFN-γ production by activated PBMCs in both healthy volunteers and RA patients in the presence of A77-1726, without a clear-cut effect on IL-6 production. IL-6 production by monocytes was not inhibited (measured by ELISA and PCR). Production of IFN-γ by lymphocytes was inhibited by A77-1726.
Conclusion:
The results presented here show inhibition of IFN-γ production by leflunomide without a clear-cut effect on IL-6 production. This differential effect supports the hypothesis that leflunomide preferentially affects activated T cells. The effects on T cells could be explained by both DHODH inhibition and effects on signal transduction pathways.
Background:
We have earlier shown that polyethylene glycol (PEG) precipitates from sera of active SLE patients can induce monokine production, possibly through immune complexes. Objective: We have now investigated monokine production induced by PEG precipitates from arthritis patients. Methods: Paired synovial fluid (SF) and serum samples from 26 RA patients and 20 patients with other inflammatory arthritides were subjected to combined PEG precipitation and purification. The IgG content was determined by ELISA. Precipitates were added to peripheral blood mononuclear cell (PBMC) cultures, and supernatant levels of TNF-α and IL-10 determined by ELISA after 20 hours. Results: In both the investigated PBMC donors, the highest median values of TNF-α were found in SF-PEG cultures. In one of the PBMC donors, this difference was significant in paired analysis for all patients and for the RA group only, but not for non-RA patients only. The correlation between the TNF-α and IL-10 production was higher for RA than for non-RA patients, and higher for SF than for serum precipitates. No correlation was noted between the IgG content of the precipitates and cytokine levels.
Conclusion:
In this preliminary study, PEG precipitates from RA SF induced higher production of TNF-α than did corresponding serum precipitates, possibly through stimulation by immune complexes in SF. Since no correlation was observed between the IgG content and cytokine induction, it is likely that immune-complex composition rather than the IgG content of the precipitates determines the cytokine response. 
Methods:
We looked at the phenotype of IL-17 and IFN-γ-producing cells by immunohistochemistry, using the CD3 and CD4 T-cell markers, the CD20 B-cell marker, the CD38, and the kappa and lambda light-chain immunoglobulins plasmocytes markers. We also focused on the expression of two chemokine receptors, CCR6 and CCR7, involved with their associated ligands CCL20 and CC19/CCL21 in the migration of T lymphocytes. Results and conclusions: IL-17 and IFN-γ-producing cells acquire a plasma-cell-like morphotype associated with the reduced expression of CD3 and the persistence of CD4 after both polyclonal and oligoclonal activation. In RA, DM, and activated lymph nodes, IL-17-and IFN-γ-producing cells presented the same morphotype. In RA synovium, these plasmacytoid-like Th1-producing cells still express the CD4 marker but not the CD3 and are CD20 -, CD38 -, kappa -and lambda -. In both in vitro and in vivo conditions, some of the Th1-producing cells can produce the CCR6 and CCR7 chemokine receptors, a finding which supports the argument that CCL20/CCR6 and CCL19,21/CCR7 play a role in the homing of T cells. Objectives: We analyzed the effects of the active metabolite of leflunomide, A77-1726, on IL-1Ra production by chondrocytes and synovial fibroblasts, with regards to the relevance of its use in RA and other cartilage damaging diseases. Methods and results: Cartilage was obtained from joints replaced for osteoarthritis or broken femoral neck. Synovial membranes were obtained from joints replaced for osteoarthritis. Cells were isolated by collagenase digestion; chondrocytes were used either directly (primary cells) or between passages 1 and 5 (dedifferentiated cells). IL-1Ra concentrations in cell conditioned media (CM) or cell lysates were assessed using a sandwich ELISA. In chondrocytes and synoviocytes, A77-1726 dose-dependently enhanced the stimulatory effects of IL-1β or TNF on IL1Ra production (average 2 fold increase in primary chondrocytes, 10 fold increase in synoviocytes). A maximal response was observed at 100 µM.
In synoviocytes, A77-1726 increased the production of soluble (s; as measured in CM) and intracellular (ic; as measured in cell lysates) IL1Ra; in contrast, no significant amounts of icIL-1Ra were recovered from primary chondrocytes. We next investigated putative pathways involved, first focusing on known effects of A77-1726 on uridine and prostaglandin E 2 (PGE 2 ) synthesis. The addition of exogenous uridine did not modify the effects of A77-1726. The addition of PGE 2 partially reversed the effects of A77-1726 in chondrocytes and synoviocytes. Indomethacin also increased IL-1Ra production, although less potently than A77-1726, and its effects were completely annulled by low doses of PGE 2 . A77-1726 at 100 µM inhibited by 95-98% the production of PGE 2 induced by IL-1β and TNF-α; this was not significantly different from the inhibition achieved by optimal doses of indomethacin. Conclusion: A77-1726 may thus possess chondroprotective effects by increasing IL-1Ra release by chondrocytes and synoviocytes. The effects of A77-1726 seem to arise partially through inhibition of PGE 2 synthesis, but other mechanisms likely concur to its stimulatory effect on IL-1Ra production.
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The Th2 Background: IL-10 has been shown to be beneficial in a series of ailments, inflammatory arthritis among them. Objective: In an attempt to study possible mechanisms we investigated the effect of IL-10 on mRNA accumulation of genes encoding hyaluronan. Hyaluronan and/or its degradation products have been implicated in the many detrimental effects associated with disease progression. Here we report that IL-10 suppresses noninduced as well as induced mRNA accumulation of certain genes encoding hyaluronan. Methods: Human fibroblast-like synovial cells (FS) were studied for their potential to synthesize hyaluronan synthase (HAS) mRNA. Expression levels of mRNA for HAS1, HAS2 and HAS3 were monitored by RT-PCR. IL-10 was added to FS cultures for 6 hours. HAS3 is constitutively expressed in FS. We found that treating FS with IL-10 inhibited HAS3 mRNA accumulation in a dose-dependent manner. Similar to HAS3, HAS2 mRNA was readily detectable in unstimulated FS. Our experiments show that in contrast to HAS3, IL-10 has no significant effect on HAS2 mRNA. Furthermore, in contrast to HAS3 and HAS2 mRNA levels in untreated FS, HAS1 mRNA is below or close to the detection limit in unstimulated FS but can be readily induced by stimulating these cells with TGF-β (1 ng/ml for 6 hours). We tested the potential of IL-10 to inhibit TGF-β-induced HAS1 mRNA synthase and found that IL-10 also inhibited TGF-β induced HAS1 mRNA, albeit to a lesser degree. Conclusion: IL-10 can be a potent inhibitor of induced as well as noninduced HAS activation. While 10 ng/ml of IL-10 can reduce HAS3 levels in FS by more than 90%, the effect of IL-10 on TGF-β induced HAS1 levels is less pronounced. Taken together, it is tempting to speculate that the observed beneficial effects of IL-10 in rheumatoid arthritis are at least in part due to its inhibitory effect on HAS mRNA activation. because of infections and 11% because of allergic reactions). No patient discontinued therapy for any reason after the 30th week. All clinical parameters were significantly improved (P < 0.01) after the fourth infusion. Forty-five patients completed 6 infliximab infusions (mean 30 weeks) and 29 of them 12 infusions (mean 75 weeks of treatment). In the last group, clinical response was sustained throughout the 75 weeks of treatment and the dose of prednisolone was significantly decreased (P < 0.0001) while 24% (6 of 25) of patients discontinued steroids. To achieve clinical response, the frequency of infliximab infusions was increased to every 6 weeks in 31% of patients, while methotrexate was significantly increased in 38% of patients (21 patients, mean dose from 10.1 to 12.3 mg/wk, P < 0.04).
Conclusion:
The clinical response of RA patients treated with infliximab is sustained during 75 weeks of treatment. However, in approximately one-third of patients, the frequency of infliximab infusions has to increase after initial response in order to sustain it. Background: The mechanism of action of TNF-α-targeted therapies, which may have a beneficial effect soon after initiation of treatment in rheumatoid arthritis (RA) patients, is as yet not completely understood. Previous work has shown that TNF-α blockade results in decreased cellularity in the synovium, which can be explained in part by reduced cell migration. In the present study we investigated whether treatment with the chimeric anti-TNF-α antibody infliximab could also reduce cellularity by induction of apoptosis in the RA synovium. Methods: Twenty-four RA patients with active disease (DAS 4.8 or higher), who had failed at least 2 DMARDs, were randomized to receive either infliximab (3 mg/kg) (n = 12) or placebo (n = 12) intravenously. All 24 patients were subjected to an arthroscopic synovial biopsy directly before initiation of treatment. In all 24 patients, a second arthroscopic synovial biopsy of the same index joint was performed 48 hours after the first procedure. After the second arthroscopy, the patients who had initially received placebo were also treated with infliximab (3 mg/kg) in an extension study. Background: A large body of evidence implicates interleukin (IL)-1, a proinflammatory cytokine, in the pathogenesis of a variety of human inflammatory disorders such as rheumatoid arthritis (RA). RA patients experience a markedly increased frequency of cardiovascular disease. IL-1 is expressed within the endothelium of atherosclerotic plaques and may participate in inflammatory mechanisms of atherogenesis. IL-1 receptor antagonist (IL-1Ra) is a natural IL-1 inhibitor. The term 'IL-1Ra' refers to four different isoforms, one of which is secreted (sIL-1Ra) and the other three of which are intracellular (icIL-1Ra1, 2, 3). sIL-1Ra competitively inhibits receptor binding of IL-1. In patients with RA, the administration of recombinant human sIL-1Ra ameliorates the clinical parameters of disease activity and decreases the progression of joint damage. Objective: The purpose of this study was to determine whether sIL-1Ra influences the formation of atherosclerotic plaques in vivo. Methods: Transgenic mice expressing high amounts of human sIL-1Ra were crossed with apolipoprotein-E-deficient mice (ApoE -/-), which develop atherosclerotic lesions when fed a high-cholesterol diet, in order to obtain ApoE -/-IL-1Ra-wild-type and ApoE -/-IL-1Ra-transgenic mice of identical genetic background. Twelve-week-old males of both groups (n = 6 per group) were fed a cholesterol-rich diet (1.25%) for 10 weeks. Increase in serum lipid profiles (total cholesterol, triglycerides) did not differ between both groups. Development of atherosclerotic lesions was measured as the extent of sudanophilic lesions, by computer image analysis.
Results:
The average lesion area within aortic roots was significantly decreased (47%, P < 0.001) in transgenic mice (0.49 ± 0.06 mm 2 ) as compared with controls (0.93 ± 0.05 mm 2 ). The extent of sudanophilic lesions was also reduced within the thoracoabdominal aorta in transgenic mice (-36%). Preliminary analysis of the cellular composition of atherosclerotic plaques showed a decrease in the percentage of macrophage-positive areas (-49%) in IL-1Ra transgenic mice as compared with control mice.
Conclusion:
Our results show that sIL-1Ra exerts a protective effect on the progression of atherosclerosis in mice. These findings suggest that the administration of IL-1Ra may also exert beneficial effects on cardiovascular complications in patients with RA. Methods: Therefore, we established human Th1 T-cell and Th2 T-cell clones, which were treated with anti-human CD4 antibodies. The T-cell clones were stimulated via the T-cell receptor and the CD28 molecule, and cytokine production was determined for TNF-α, IFN-γ and IL-4. Results: TNF-α and Interferon-γ are produced exclusively by Th1-T cells and inhibition of cytokine production by anti-CD4 was nearly total for TNF-α production but much less pronounced for IFN-γ. No effect of anti-CD4 on IL-4 production in human Th2 T-cell clones was observed. Conclusion: Our data may help us to understand the mechanisms of anti-CD4-mediated modulation of immune responses. The CIS thus provides a GATA-3 specific nucleus of epigenetic modification of the IL-4 gene, imprinting it for memory expression upon restimulation of the T cell by antigen alone. S19 are poorly understood. Interleukin-10 (IL-10) is known for its wide range of both anti-inflammatory and inflammatory effects on various cell types involved in RA. Objective: To gain a better understanding of the role of IL-10 in RA, we analyzed in a prospective cohort of RA patients (n = 283) the -2849 A/G IL-10 promoter polymorphism, as this polymorphism is highly associated with high (AG/GG variants) or low (AA variant) IL-10 production. Results: In our cohort, the IL-10 genotype was, in comparison with controls, not a risk factor for RA. But,RA patients with the -2849 genotypes associated with high IL-10 production, had, at baseline, significantly higher titers of IgG autoantibody (anti-CCP and IgG rheumatoid factor), but not of IgM autoantibody (IgM rheumatoid factor). Moreover, a higher rate of joint destruction was observed in RA with genotypes associated with high IL-10 production. However, invasiveness of fibroblast-like synoviocytes, which are thought to be important effectors of joint destruction, was not correlated with IL-10 genotypes.
A GATA-3 binding site in the first intron of the interleukin-4 gene defines a critical element for the memory expression of interleukin-4 in Th lymphocytes
Conclusion:
The -2849 IL-10 promoter polymorphims associated with high IL-10 production were found in RA patients with high IgG autoantibody titers and an increased rate of joint destruction. As IL-10 is crucially involved in class-switching and function of B-cells, we propose that genetically determined differences in IL-10 production mediate their effect on joint destruction via increased autoantibody production by B cells. Objective: We tested the association of certain cytokine gene polymorphisms with juvenile idiopathic arthritis (JIA) in Czech Caucasians.
Methods:
In a case-control study, genotypes of 130 patients with JIA (63 males, 67 females; age at onset 7.6 ± 4.4 years; 43 oligoarticular, 72 polyarticular, 15 systemic form) were compared with those of 102 healthy unrelated blood donors. Using polymerase chain reaction with sequence-specific primers designed by J Mytilineos, 24 singlenucleotide polymorphisms were tested within 13 different genes for cytokines (IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-α, TGF-1β, INF-γ) and related molecules (IL-1R, IL-1RA, IL-4Rα). Risk was expressed using OR calculated from allelic, genotypic, and phenotypic frequencies, and the P values were corrected for 13 tested molecules. Results: Two polymorphisms were significantly associated with JIA. The IL4 -1098 G phenotype was present in 10% of cases and 25% of controls (OR = 0.32, CI 95% 0.16-0.67, P corrected = 0.039). The IL-1β +3962 C phenotype was present in 96% of cases and 84% of controls (OR = 4.65, CI 95% 1.64-13.2, P corrected = 0.05). There was also a tendency towards a lower prevalence of the TNF-α -238 A phenotype in cases (5%) than in controls (16%), but it became insignificant after correction for the number of tested molecules. Conclusions: Our associations with IL-1β or with IL-4 have not been yet reported from other populations. Acknowledgement: Supported by grant MSMT CR 111 300 003 and MZ CR 0000 6042.
Molecular cross-talk between the TRAIL and TGF-β β pathways in human lung fibroblasts VV Yurovsky
University of Maryland School of Medicine, Baltimore, MD, USA Arthritis Res Ther 2003, 5 (suppl 1):64
Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) has been closely associated with regulation of the immune response and pathogenesis of autoimmune diseases. The expression of TRAIL was found in CD8 T cells that had undergone oligoclonal expansion in the lungs of patients with systemic sclerosis and were able to stimulate collagen production in lung fibroblasts. Soluble, multimerized TRAIL and normal human lung fibroblasts were used as a model of selective TRAIL influence on fibroblasts. TRAIL was found to increase both α2(I) collagen mRNA expression and total soluble collagen secretion, with peak response at 1 ng/ml TRAIL. DNA microarray analysis suggested that fibroblast response to TRAIL might be mediated by c-Jun N-terminal kinase (JNK). The increase in JNK1 expression and phosphorylation as well as phosphorylation of its specific substrate were confirmed by Western blotting. The treatment of fibroblasts with TRAIL also enhanced the expression of a number of genes involved in tissue remodeling, including those related to the transforming growth factor (TGF) beta pathway. The increase in TGF-β1 mRNA level was confirmed by Northern blotting and by measurements of active TGF-β1 in culture supernatants. In addition, antibody-mediated blocking of TGF-β was shown to abrogate TRAIL-induced collagen synthesis. These data suggest that TRAIL can enhance extracellular matrix production in fibroblasts by triggering expression of TGF-β, which acts in an autocrine manner. If this process continues uncontrolled, it may contribute to the development of fibrosis, particularly in the lungs of patients with systemic sclerosis.
To investigate the efficacy of isolated and combined blockade of TNF-, IL-1-and RANKL-pathways on synovial inflammation, bone erosion and cartilage destruction in a TNF-driven arthritis model, human TNF transgenic (hTNFtg) mice were treated with anti-TNF (infliximab), IL-1 receptor antagonist (IL-1Ra) or osteoprotegerin (OPG). In addition, each of three possible double combination therapies and a triple combination therapy was applied. Therapy was followed by histological assessment of synovial inflammation, bone erosion and cartilage damage. Synovial inflammation was inhibited by anti-TNF (-51%), but not IL-1Ra or OPG monotherapy. Combinations of anti-TNF with IL-1Ra (-91%) or OPG (-81%) were additive and almost completely blocked inflammation. Bone erosion was effectively blocked by anti-TNF (-79%) and also by OPG (-60%), but not by IL-1Ra monotherapy. Combination of anti-TNF and IL-1Ra, however, completely blocked bone erosion (-98%). The effects on inhibition of bone erosion were accompanied by reduction of osteoclast numbers within synovial tissue. Cartilage destruction was inhibited by anti-TNF (-43%), weakly, but not significantly by IL-1Ra, and not at all by OPG monotherapy. Combination of anti-TNF with IL-1Ra was the most effective double combination therapy in preventing cartilage destruction (-80%). In all analyses, a triple combination of anti-TNF, IL-1Ra and OPG was not superior to double combination therapy with anti-TNF and IL-1Ra. Articular changes caused by chronic TNF overexpression are not completely blockable by monotherapies, which target TNF, IL-1 or RANKL. However, combined approaches that reduce TNF load and block IL-1 or RANKL as downstream mediators of TNF can lead to a complete remission. Differences in their efficacy to block synovial inflammation, bone erosion and cartilage destruction further strengthen the rationale for combined blockade of more than one proinflammatory pathway. HLA-B27/hb2-microglobulin transgenic rats spontaneously develop a multisystem inflammatory disease resembling the human spondyloarthropathies. This disease in rats is dependent on the presence of a bacterial flora and mediated by T cells, but antigen-presenting cells (APCs) may also play a critical role. Splenic dendritic cells (DCs) have been reported to be defective in allogeneic mlR in this model. Here, we investigated the functional defect of APCs. We observed a defective stimulation of allogeneic and syngeneic CD4 + , and CD8 + LN T lymphocytes, by DC and B cells, from disease-prone 33-3 HLA-B27 transgenic, but not from healthy homozygous 120-4 HLA-B7 transgenic rats, even if stimulation was driven in the presence of Con A or anti-TCR mAbs. Pretreatment of HLA-B27 DCs with lipopolysaccharide or IFN-γ did not enhance their stimulatory capacity. In competitive culture, and transwell assay, we found no evidence for an inhibitory factor or a lack of diffusible factor produced by HLA-B27 DCs. When comparing class II MHC, CD2, B7, ICAM1, and LFA-1 molecules at the surface of DC from 33-3, 120-4, and nontransgenic rats, we found no difference. However, the proportion of conjugates formed between Results: Significant increases in severity and collagen-specific antibodies were seen in mice that were depleted before immunization with collagen. In vitro tests with splenocytes from depleted mice also showed increased proliferation of collagen-specific T cells, indicating that CD25 + regulatory cells are involved in CIA. In humans, the HLA-DQ8 molecule is strongly associated with rheumatoid arthritis. Since CD25 + CD4 + T regulatory cells are probably selected in the thymus, specific MHC class II molecules could hinder their development, which could explain the association between HLA and disease susceptibility. In order to explore this possibility, we performed similar experiments in HLA-DQ8 transgenic mice. We found that depletion of CD25 + cells had the same effect on CIA as seen in the DBA/1 mice. Furthermore, DQ8-restricted CD25 + CD4 + T cells were found to be as capable of suppressing the proliferation of PHA stimulated splenocytes as CD25 + CD4 + T regulatory cells isolated from DBA/1 mice. Conclusion: These findings indicate that CD25 + regulatory cells can modulate arthritis and that HLA-DQ8 does not interfere in the generation of functional CD25 + CD4 + T regulatory cells. Background: Direct intra-articular gene tranfer with adeno-associated virus (AAV) vectors is a promising strategy to allow efficient therapeutic transgene expression within the joint. However, over 90% of humans Available online http://arthritis-research.com/supplements/5/S1 S22 demonstrate antibodies against AAV which could alter AAV transduction efficiency in vivo. Objective: Our objective was to determine the influence of synovial fluid (SF) and serum from arthritic patients on AAV-mediated gene transfer to chondrocytes in vitro. Methods: SF and sera derived from 21 patients suffering from various (inflammatory or mechanical) origins were collected. Neutralizing activity against AAV/IL-4 was determined by assessing the ability of SF or serum to inhibit transduction of AAV/IL-4 into the C20A4 human chondrocyte cell line. Total IgGs were purified from SF by salt-dependent chromatography.
MHC and autoimmune disease
Results: In SF and sera, inhibition of AAV-mediated gene transfer to chondrocytes was observed in all arthritic patients. Purified IgG from SF exhibited inhibition patterns similar to those seen with unfractionated SF. A correlation was observed between levels of inhibition by the SF and the serum (P < 0.0001, r = 0.813). Lastly, we have shown that the inhibition of AAV/IL-4 infection on C20A4 cells by SF and sera could be reversed by increasing the number of AAV/IL-4 particles, with a dose-dependent effect. Conclusion: SF and sera from all patients show a neutralizing activity against AAV infection on chondrocytes. Neutralizing factors were IgG antibodies present in the SF. This inhibition can be reversed by increasing AAV doses. In the future, these data might be useful to adapt intraarticular AAV gene therapy to each individual patient. Background: The Dox-inducible reverse tetracycline transactivator (rtTA) is often used to control gene activity in cells and transgenic animals. However, the Tet-on system is limited by the high levels of transgene expression in the absence of doxycycline administration. Objective and methods: To overcome this unregulated expression, we used the tetracycline-dependent transcriptional silencer (tTS) that binds the tetO inducible promoter in the absence of Dox. Controlled gene expression was analyzed in vivo by delivering combinations of the Dox-regulated luciferase reporter construct, the rtTA and the tTS expression plasmids into the tibialis anterior muscles of adult mice, using electrotransfer. Results: Elevated luciferase expression levels were observed in the absence of doxycycline, and a 10-fold induction was obtained after drug administration. In contrast, when tTS was added, background expression was dramatically lowered, by three to four orders of magnitude, and induction was maintained. The tTS system was then used to control expression of a therapeutic gene in experimental arthritis. The tibialis anterior muscle of DBA1 mice was coinjected with plasmids encoding the anti-inflammatory cytokine viral interleukin-10 (vIL-10) under the control of the tetO promoter, the rtTA and tTS. Electroporation of injected muscles resulted in a dose-dependent increase in vIL-10 expression, maintained over a 3-month period. The Dox-regulated vIL-10 secretion showed significant inhibitory effects on collageninduced arthritis, as paw swelling was reduced and the onset of disease was delayed in the Dox-treated group in comparison with the control group without Dox.
Conclusion:
The use of tTS significantly improves the utility of the rtTA system for somatic gene transfer by reducing background activity. Objective: Therefore, we explored the immunological effects of differentially matured DCs on the development of collagen-induced arthritis in mice. Methods: Murine bone-marrow-derived DCs where cultured in the presence of granulocyte/macrophage-colony-stimulating factor and IL-4 and incubated with collagen type II (CII). Maturation of the DCs was blocked with IL-10, or induced with TNF-α or lipopolysaccharide (LPS). The DC differentiation and maturation steps were controlled by CD11c and CD86 expression, which was assessed by flow cytometry. Seven days before immunisation with bovine CII, mice were injected intraperitoneally with 500,000 DCs obtained at different stages of maturation. Mice were boosted on day 21 after arthritis induction and the disease course was monitored until day 43. DC function was assessed through mlR assays.
Results: While injection with IL-10-blocked or LPS-matured DCs had no significant influence on the onset and development of arthritis, administration of TNF-matured DCs resulted in a reduction of arthritis severity in comparison with the control group. In contrast, mice treated with immature DCs showed a delayed arthritis onset and a decrease in the arthritis clinical score.
Conclusions:
Collagen-induced arthritis may be prevented by pretreatment with antigen-specific immature DCs or TNF-matured DCs. Furthermore, the principle of DC-mediated tolerance may have promising immunotherapeutic potential in arthritis.
Background and objective: Synovial membrane fibroblasts in rheumatoid arthritis induce the destruction of cartilage and bone. We have isolated a fibroblast cell line which induces a rapid destruction of articular cartilage following intraarticular instillation in SCID mice and in vitro. Both approaches can be modulated by gene transfer. Methods: As a cytokine with functions directed to inflammatory and immune cells as well as fibroblasts, interleukin-11 was selected to modulate invasive behaviour of fibroblasts. For transduction, a retroviral vector system, particle-mediated transfer (gene gun), and a lentiviral vector based on simian immunodeficiency virus were investigated. Cells (500,000) were injected directly into the knee joinst of mice with severe combined immunodeficiency (SCID). Mice were monitored for joint swelling, serological parameters and by radiological methods.
In vitro, cells were coincubated with cartilage for 1 week. Finally, the histology of cartilage destruction and signs of apoptosis were studied.
Results:
The efficacy of gene transfer was <10% for retroviral transfer or gene gun but >85% for lentiviral transfer. Therefore, animal testing and in vitro assays were performed with lentiviral-transfected cells in comparison with nontransfected invasive fibroblasts and control cells. Cartilage destruction within 10 days was induced by instillation of nontransfected cells. Morphology revealed invasion of fibroblast-like cells into the articular cartilage. Transfection with interleukin-11 did not act on swelling but slightly reduced cartilage invasion. In vitro, this effect was caused by reduction of apoptosis in chondrocytes. Conclusion: Induction of cartilage destruction by intraarticular application of fibroblast like cells into SCID mice can be modulated by gene transfer. Lentiviral vectors systems offer a novel approach for highly efficient transduction of these cells. This model provides the opportunity to check novel therapeutic strategies for reduction of cartilage erosion. Background: Interleukin-4 (IL-4) has anti-inflammatory effects in collagen-induced arthritis (CIA). Osteoprotegerin (OPG) inhibits bone resorption by binding the receptor activator of nuclear factor κB ligand (RANKL) and thereby inhibits binding of RANKL to RANK (receptor activator of nuclear factor κB) receptors of osteoclast precursors. Objectives: To evaluate the action of OPG and IL-4 on the inflammatory process and the bone resorption associated with the inflammation. Methods: CIA was induced in DBA/1 mice by immunization with bovine type II collagen (CII). Mice were treated by subcutaneous injections of OPG-Fc or with IL-4 DBA/1-transfected fibroblasts or both OPG-Fc+IL-4. Control groups received DBA/Tst or I1gG or saline. In one group CIA was not induced. Urinary deoxypyridinolin levels and total-body bone mineral density (BMD, Piximus Lunar) were measured at baseline and at sacrifice, allowing the measure of bone gain (BMD). Spleen cells were cultured after stimulation with CII, and cytokines were measured in the supernatants using ELISA techniques. Results: CIA significantly improved in the IL-4 groups. OPG had no effect on arthritis clinical scores but histologic scores were reduced in OPG, IL-4 and OPG+IL-4 groups versus nontreated CIA mice. Treatment with OPG significantly increased BMD in the total body. Moreover, the combination of IL-4 and OPG exerted an additive effect of BMD. D-pyridinolin levels decreased by 45% in OPG-treated mice and by 68% when mice were treated with both OPG and IL-4. INF-γ production was inhibited in IL-4 treated mice in comparison with controls. Interestingly, OPG also had a moderate effect on IFN-γ but potentiated the inhibitory effect observed in IL-4-treated mice. Background and objective: Most antirheumatic therapies are given systemically, which may result in complications because of the high dosage needed to achieve therapeutic levels in the joints. Gene therapy might provide a more efficient system to deliver therapeutic compounds at the site of inflammation. The artificial chromosome expression system (ACes) is a unique, nonintegrating, nonviral gene-expression system, which functions like a natural chromosome. This technology offers advantages over current expression systems because it allows stable expression of genes producing single or multiple proteins over long periods. We are developing ex vivo gene therapy using artificial chromosomes containing reporter genes (LacZ or RFP) for local delivery of genes in rats with adjuvant arthritis. The aim of this study was to evaluate the transfection efficiency in cell lines or primary cells, including rat skin fibroblasts (RSFs) and fibroblast-like synoviocytes (FLSs). Furthermore, we investigated the feasibility of local delivery of a marker gene to the joints of rats with adjuvant arthritis (AA) by ex vivo gene therapy. Methods: Transfer efficiency and optimal dose of transfection agent were determined using iododeoxyuridine (IdUrd)-incorporated ACes complexed to Superfect (Qiagen) (Cytometry Vol 44:100-105, 2001 Objective: For 20 years the Epstein-Barr virus (EBV) has been suspected to contribute to the pathogenesis of rheumatoid arthritis (RA). RA is strongly associated with shared epitope positive HLA-DR alleles. EBV load has been extensively studied in RA patients, using semiquantitative PCR. Inconsistent results reflect the lack of sensitivity and accuracy of this technique. We quantified EBV in peripheral blood mononuclear cells by real time PCR, to determine whether EBV load is higher in RA patients than in controls and to test whether HLA-DR alleles or treatment influences EBV load. Methods: Eighty-four patients fulfilling the 1987 ACR criteria for RA and 22 patients with rheumatic conditions other than RA were studied. Sixty-nine healthy controls were chosen from bone marrow donors at the Marseille blood transfusion center. HLA-DR genotyping of patients and controls was performed by PCR-SSP. Real-time PCR was performed using a Roche LightCycler. A 214-bp fragment from the highly conserved long internal repeat IR1 was amplified. Two specific hybridization probes were used to recognize adjacent internal sequences within the target. EBV-positive Burkitt's lymphoma cell line was used as an external standard. Results and conclusion: EBV load is expressed in EBV genome copy number per 500 ng of human genomic DNA (1.5 × 105 cells). We found that patients with RA have a higher EBV load (median 8.84) than non-RA patients (median 1.56) and healthy controls (median 0.6). EBV load is not obviously influenced by disease-modifying antirheumatic drugs nor by HLA-DR and is stable over time. Background: Bacterial infections are common and are known to be involved in many diseases including arthritis. While some methods for detecting bacteria are time-consuming, others are faster but lack specificity and/or sensitivity.
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Methods and results:
We employed a new method for DNA isolation and compared the results with those of an established method. We show that an equivalent of fewer than 10 bacteria of Staphylococcus aureus (SA), methicillin-resistant Staphylococcus aureus, Staphylococcus epidermitis (SE) or bacteria in general can be detected in less than 2 hours. We found that lyses in a SDS/β-mercaptoethanol buffer and exposure to microwaves is as well suited for detecting fewer than 10 microorganisms per sample as a longer, more elaborate and more expensive method using specific enzymes. We further confirmed the sensitivity of our multiplex PCR method by recovery experiments using known amounts of bacteria. Such experiments showed that bacteria present in single-digit quantities can be detected even in viscous solutions such as synovial fluid. We further showed that the chosen primer pairs are suited for multiplex PCR, the simultaneous testing of samples for the presence of SA, SE, and/or bacteria in general. We also showed that the assay conditions are suitable for detecting the presence of methicillin-resistant forms of SA. The specificity of the PCR was confirmed by comparison of the actual size with the calculated length of the fragment, and by sequencing of the PCR product. Conclusion: Taken together, our method of rapid DNA isolation and the optimized PCR program make it possible to confirm the presence or absence of minute amounts of bacteria. Employing real-time PCR would shorten this procedure even further. This method might therefore contribute to more timely and specific interventions.
Increased frequency of T cells specific for EBV gp110 in the synovial fluid of patients with rheumatoid arthritis
Background: Antilipemic agents such as statins are extensively used for the acute and long-term treatment of cardiovasular disease. Adverse muscle effects commonly include myalgias and elevated serum creatine kinase whereas a few fatal cases associated with myoglobinuria and renal failure have been described recently.
Objective: The purpose of the present study was to investigate muscle contraction using in vitro contracture tests (IVCT) in patients with adverse effects from anticholesterolemic treatment. Methods: Two patients with statin-therapy-induced mylagias and rhabdomyolysis were included in the study. They were investigated 6 months after discontinuation of statin treatment, when signs of rhabdomyolysis had disappeared. In vitro contracture tests in the presence of halothane or caffeine were performed in accordance with the guidelines to the European Malignant Hyperpyrexia Group. Results: Histological and immunohistochemical analyses showed signs of rhabdomyolysis. Abnormal muscle contracture was measured with both halothane and caffeine in the first patient. For the second patient, muscle samples developed abnormal contracture with halothane only. Both patients were diagnosed as having malignant hyperthermia syndrome.
Conclusion:
Our results further confirm the myotoxic effects of treatment with statins. We report for the first time these effects in patients with malignant hyperthermia syndrome for whom calcium homeostasis is impaired in skeletal muscle. This impairment is commonly attributed to a genetic defect affecting the ryanodine receptor, one of the calcium channels in the sarcoplasmic reticulum membrane. Our result suggest that toxic rhabdomyolysis could be a sign of susceptibility to malignant hyperthermia and that muscle contraction should be investigated, using IVCT, in subjects who develop myalgia with rhabdomyolysis during treatment with statins.
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positive predictive value (PPV) of single histological markers and the additive value of multiparameter models. Methods: Synovial biopsies were obtained in 154 consecutive patients presenting for diagnostic work-out: 67 were clinically classified as rheumatoid arthritis (RA), spondyloarthropathy (SpA), or other disease at time of arthroscopy (cohort 1). Patients with undifferentiated arthritis (n = 87) were re-evaluated after 6 months, yielding a diagnosis in 53 (cohort 2). Macroscopic, histological, and immunohistochemical synovial parameters with diagnostic value were identified in cohort 1. Subsequently, the PPV of single parameters and multiparameter models was tested in cohort 2. Background: Proinflammatory or anti-inflammatory roles have been ascribed to leptin, depending on the experimental model investigated.
We recently observed decreased severity of antigen-induced arthritis (AIA) in leptin-deficient ob/ob mice. However, joint inflammation in AIA depends on the immune response to an exogenous antigen, which is impaired in ob/ob mice. Objective: The aim of the present study was to investigate potential effects of leptin in zymosan-induced arthritis (ZIA), a model of acute inflammatory arthritis, which is not dependent on the adaptive immune response.
Methods and results:
Arthritis was induced in ob/ob and control +/? C57BL/6 mice by injection of zymosan A (Zy) into the knee joint cavity. Increased blood flow, reflecting the severity of joint inflammation, was quantified by uptake of technetium 99 m. It was similar 6 and 24 hours after Zy injection in ob/ob and control mice. However, it persisted on day 3 in ob/ob animals, while subsiding in controls. Histology repeatedly showed similar severity of arthritis in ob/ob mice and controls on day 3, but arthritis always tended to be more severe in ob/ob than in +/? mice at later time points (days 14 and 21). Similar observations were made using leptin-receptor-deficient db/db mice, suggesting that the effects of leptin are mediated via the Ob-Rb receptor. The acutephase response was examined in ob/ob and control mice after injection of Zy by measuring circulating levels of interleukin (IL)-6 and serum amyloid A (SAA). Serum IL-6 increased in all animals during the first 24 hours after Zy injection, but IL-6 levels were significantly higher in ob/ob mice than in controls. SAA increased in all animals during the first 3 days after Zy injection, but SAA levels were significantly higher on days 1 and 3 in ob/ob animals than in controls. The acute-phase response thus appeared to be more pronounced in ob/ob mice, although corticosterone levels were significantly elevated in these animals at baseline and throughout the experiment Conclusion: These data suggest that the resolution of acute inflammation during ZIA is delayed in leptin-deficient animals. Background and objective: Depletion of platelets reduces influx of hemopoietic cells into the glomeruli, decreases resident cell proliferation and improves renal function in animal models of glomerulonephritis. However, the precise mechanisms by which platelets promote glomerular injury are poorly understood. We explored whether platelets induce production of monocyte chemoattractant protein-1 (MCP-1) by cultured human mesangial cells (MCs) and the mechanisms involved. Methods: Platelets were isolated from normal human donors and cocultured with MCs at various ratios. The contribution of cell-to-cell contact was examined by a double-chamber culture system. MCP-1 synthesis in cocultures was determined by semiquantitative reverse transcription/real-time PCR and ELISA. Signal transduction was studied by mobility gel-shift assays and phosphotyrosine immunoblots. Results: Platelets, at 1:100 ratio (MC : platelets), induced a more than 10-fold increase in mesangial MCP-1 production, both in mRNA and protein levels. Using a double-chamber culture system, we demonstrated that the direct cell-to-cell contact between platelets and MC is indispensable for MCP-1 production. Importantly, blockade of the CD40-CD40 ligand (CD40L) pathway with neutralizing antibodies decreased MCP-1 production by approximately 60%. Immunostaining confirmed the expression of CD40 by cultured MCs. When added into MC cultures, recombinant CD40L in combination with recombinant IFN-γ, enhanced MCP-1 production twofold (relative to the basal levels in response to recombinant IFN-γ alone), confirming that CD40 was functionally expressed on MCs. Using gel-shift assay and a specific inhibitors, we showed that the contact of MCs with platelets induced NF-κB activation, which was essential for MCP-1 synthesis. In additional experiments, we found that activation of p38 mitogen-activated protein kinase (MAPK) and protein tyrosine kinases (PTKs) are involved in platelet-mediated MCP-1 induction by MCs. Conclusion: Platelet/MC contact stimulates the production of MCP-1 and may contribute to glomerular inflammatory responses by recruiting leukocytes from the peripheral blood. Background: Chronic exposure of CD4 + T cells to picomolar concentrations of tumour necrosis factor alpha (TNF) induces a hyporesponsive phenotype, as measured by T-cell-receptor-(TCR)-stimulated proliferation and cytokine production, which is similar to that of T cells recovered from inflamed rheumatoid synovial joints. We have reported previously that chronic exposure to TNF impairs assembly of the TCR/CD3 complex at the cell surface by down-regulating expression of the signal amplification module TCR zeta (TCR-ζ). TCR-induced tyrosine phosphorylation of ZAP-70, LAT and PLC-γ1 are attenuated in TNF-treated cells as a consequence.
Objective and results:
Here we report studies of the effects of TNF on downstream signalling pathways using a murine T-cell hybridoma. We show that signalling from the TCR via the extracellular signal-regulated kinase (ERK) pathway is similar in control and TNF-treated cells, as determined by induction of GTP-bound Ras, by phosphorylation on ERK1/2 and the ERK substrate Elk-1, and by ERK-dependent expression of c-fos and CD69. By contrast, TCR-induced calcium flux is greatly attenuated in TNF-treated cells. Despite preservation of ERK signalling, induction of cytokine mRNA transcripts, whose expression depends upon calcium signals and the generation of NFAT (functional nuclear factor of activated T cells) or NFAT/AP-1 complexes, is markedly suppressed in TNF-treated T cells. Further experiments reveal that TNF alters signalling through the calcium/NFAT pathway independently of its effects on receptor-proximal events. For example, we find that whereas calcium responses induced by ionomycin or thapsigargin are similar in control and TNF-treated cells, IL-2 production is greatly reduced in TNF-treated cells as compared with controls after stimulation with phorbol ester and ionomycin. As is the case for stimulation via TCR, activation of the Ras/ERK pathway by phorbol ester is preserved in TNF-treated T cells. Conclusion: These data are consistent with a model in which TNF alters NFAT function through effects on nuclear translocation, DNA binding or transcriptional activation. The model also predicts that TNF may promote T-cell effector responses indirectly by suppressing NFATdependent genes whose expression is required for immunoregulation and peripheral tolerance.
Background: Myeloid-related protein (MRP) 8 (S100A8) and MRP 14 (S100A9) are calcium-binding proteins belonging to the S100 family. Objective: To determine immunohistological markers in synovial tissue of early rheumatoid arthritis (RA) patients, which could be used as predictors for disease outcome. Methods: Synovial tissue was obtained from 36 RA patients within 1 year after the initial symptoms and before the initiation of treatment with any disease-modifying antirheumatic drug. Clinical, laboratory, and radiological assessment (Larsen score) was performed at the time of the biopsy and at the end of follow-up (mean 58 months, range 38-72 months). Immunohistological analysis was performed to detect T cells, B cells, plasma cells, fibroblast-like synoviocytes (FLS), macrophages, and granzyme B + cytotoxic cells. The sections were evaluated by digital image analysis. Results: Patients were divided into two groups based upon the radiological progression per year of follow-up: group I with moderate progression (n = 20) (by <2 points/year, Larsen score) and group II with pronounced progression (n = 16) (by ≥2 points/year, Larsen score). Regression analysis with a univariate model revealed that female gender (RR = 10.7, P = 0.015) and numbers of granzyme B + cytotoxic cells (RR = 12, P = 0.003), T cells (RR = 10.1, P = 0.013), and FLS (RR = 10, P = 0.020) discriminated between groups I and II. A multivariate model demonstrated that female gender (RR = 78.42, P = 0.017) and numbers of T cells (RR = 1.2, P = 0.015) and FLS (RR = 1.4, P = 0.013) were independent discriminators between groups I and II.
Conclusion:
The numbers of granzyme B + cytotoxic cells, T cells, and FLS in synovial tissue of RA patients are related to the severity of joint damage and therefore may be useful prognostic markers of disease outcome in patients with recent-onset RA. In addition, the observations suggest a pathogenic role of these cells in the process of joint damage. Background: Osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) are the key regulators of osteoclastogenesis in inflammatory diseases, such as RA. OPG binds to RANKL, prevents its ligation to receptor activator of nuclear factor κB (RANK) and inhibits differentiation and activation of osteoclasts. The imbalance of this system results in the predominance of osteoresorption and bone erosions.
Objective: The aim of study was to compare the levels of OPG and soluble RANKL (sRANKL) in serum (S) and synovial fluid (SF) in rheumatoid arthritis (RA), osteoarthritis (OA) and spondylartropathies (SpA) and to correlate these levels with inflammatory parameters. We hypothesized that there is a higher local synthesis of both factors and positive correlation of sRANKL in synovial fluid with the disease activity in RA.
Methods:
The paired S and knee SF samples were collected from 105 patients with RA (n = 45), OA (n = 46) and SpA (n = 14). The OPG and sRANKL levels were measured by sandwich ELISA (Biomedica). Results: Concentrations of OPG and sRANKL were significantly higher in SF than in S in all groups (Table 1) . RA and SpA groups had S-OPG and SF-OPG lower than OA. RA and OA groups differed significantly. S-sRANKL was negative in most cases in all groups. The significant negative correlation with serum CRP and SF leukocyte count was found in S-OPG, SF-OPG and SF-sRANKL. Table 1 The mean OPG and sRANKL levels in patient cohorts
Background: In the cartilage of the joint, the matrix proteins are very pronounced in relation to the scattered chondrocytes in the tissue. In recent years, many different small molecules have been described with close relation to the collagen fibers and with activities that could be important in protecting the collagen fiber structure. One of these proteins is cartilage oligometric protein (COMP).
Available online http://arthritis-research.com/supplements/5/S1
Figure 1
Invasiveness of FLSs (in Matrigel) of two different joints from one patient. 
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Objective: The aim of our study was to investigate the serum level of COMP in psoriatic arthritis, to determine whether cartilage destruction is taking place. Methods: Thirty-six psoriatic arthritis patients (22 women, 14 men), with an avarage disease duration of 7 years, were examined. For every patient, the disease activity on a visual analogue scale, the number of painful and swollen joints and the Ritchie index were recorded, as well as the sedimenation rate and CRP. The level of COMP was measured. Correlations between the activity parameters and the level of COMP were evaluated. Results: A good correlation was found between the Ritchie index and the serum level of COMP (r = 0.4) . Low correlation was seen between the level of COMP and the number of painful joints (r = 0.1). No correlation was found between COMP and any of CRP, sedimentation rate or number of swollen joints.
Conclusion:
The serum level of COMP can be used as one of the activity indicators of arthritis activity, though the correlation with other activity parameters in PsA is not so strong as in rheumatoid arthritis. The reasons for this difference may lie in the additional activity of the skin disease.
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The inhibitory receptor Fcγ γRII reduces joint inflammation in immune complex arthritis not only by inhibition of activatory Fcγ γR but also by efficient clearance of immune complexes
